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myocardial infarction (78% versus 68%; P < 0.001). Even after multivariate adjust-
ment, MS was still associated with higher risk of in-hospital heart failure (odds ratio 
(OR), 1.37; 95% CI: 1.03–1.81; p = 0.028) and mortality (OR, 4.42; 95% CI: 
1.25–15.5; p = 0.020). CONCLUSIONS: Prevalence of MS in ACS patients in Oman 
is high and seen more in females than in males. Furthermore, MS was associated with 
higher in-hospital heart failure and mortality.
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OBJECTIVES: Despite the availability of the ESC European guidelines on cardiovas-
cular prevention, considerable cardiovascular mortality remains throughout Europe. 
The European Study on Cardiovascular Risk Prevention and Management in Daily 
Practice (EURIKA) (NCT00882336) investigated the prevalence and degree of control 
of main cardiovascular risk factors in primary prevention of cardiovascular disease 
(CVD). METHODS: EURIKA was a cross-sectional study conducted simultaneously 
in 12 European countries (n = 809 primary care and specialist physicians). Patients 
aged ≥50 years who were free of clinical CVD, but had at least one risk factor as 
deﬁ ned by the 2007 European guidelines on cardiovascular prevention, were eligible 
for inclusion. Data recorded included smoking status, body mass index, cholesterol 
levels, blood pressure and presence of diabetes. Cardiovascular risk was assessed by 
Systematic COronary Risk Evaluation (SCORE) methods. Attributable coronary mor-
tality was calculated based on our prevalence estimates together with hazard ratios 
for CVD-related mortality (from the Third National Health and Nutrition Examina-
tion Survey). RESULTS: In total, 7641 patients (mean age: 65 years; 48% male) were 
evaluated. Of those aged <65 years, 27% had a SCORE-based absolute risk of CVD 
of ≥5%. The prevalence of risk factors was 21.3% for current smoking, 71.9% for 
hypertension, 55.4% for dyslipidemia, and 26.6% for diabetes. Control of risk factors 
among patients receiving therapy was 49% (between country range: 40–61%) for 
hypertension, 48% (26–74%) for dyslipidaemia and 40% (26–54%) for diabetes. The 
adjusted excess mortality attributable to risk factors was 17% (14–25%) for current 
smoking, 23% (21–25%) for hypertension, 26% (17–31%) for dyslipidaemia, and 
30% (20–37%) for diabetes. CONCLUSIONS: The prevalence of traditional cardio-
vascular risk factors is high and their control is suboptimal. Traditional risk factors 
such as hypertension, dyslipidaemia and diabetes are responsible for a large fraction 
of the estimated coronary deaths that could be avoided through primary prevention.
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OBJECTIVES: This study aims to determine the degree of blood pressure (BP) control 
and the differences in therapeutic strategies adopted by physicians based on patients’ 
age and/or their functional status. METHODS: Multicenter and cross-sectional study 
that included patients with essential hypertension attending primary or specialist care, 
with at least one year of evolution. The study included 6453 patients, stratiﬁ ed into 
three main groups: a (<65 years) = 2184; B (65–79 years) = 2079; and C (≥80 years) 
= 2079. RESULTS: 51.3% of patients were male and mean (SD) age was 55.1 ± 7.5 
years (group A), 71.4 ± 4.0 (B) and 83.7 ± 3.2 (C). 49.1% of patients were overweight. 
Mean systolic BP values were 141.3 ± 15.6 (A), 142.0 ± 16.3 (B) and 142.3 ± 16.8 
(C) mmHg, and mean diastolic BP values were 84.5 ± 10.1 (A), 81.5 ± 10.5, 79.9 ± 
11.2 (C) mmHg. 33.5% of patients had type 2 diabetes mellitus and 59.1% dyslipid-
emia. The existence of previous cardiovascular (CVD) or renal disease has been 
established in 38.9% of cases. The prevalence of CVD was 22.6% (A), 39.1% (B) and 
55.9% (C). Target organ damage (TOD) was 26.7% (A), 40.8% (B) and 57.8% (C). 
The Barthel index that measures a person’s daily functioning reﬂ ected that the oldest 
group had a signiﬁ cantly higher level of moderate or severe dependence (P < 0.0001). 
Patients with controlled BP were 29.4% (A), 25.5% (B) and 23.7% (C) (P < 0.0001). 
Clinical inertia—the failure to intensify therapy in patients who do not achieve the 
clinical objectives—reached 60.3% (A), 61.7% (B) and 66.2% (C) (p = 0.0002), 
respectively. Global treatment compliance was 94.3%, and the difﬁ culty for taking 
the medication signiﬁ cantly increased with patients’ age (P < 0.0001). CONCLU-
SIONS: Older hypertensive patients have a poorer BP control but an increased clinical 
inertia. These patients have higher prevalence of TOD and CVD, worse functional 
status and worse treatment compliance. 
CARDIOVASCULAR DISORDERS – Cost Studies
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OBJECTIVES: The self-expandable paclitaxel DES represents a major development in 
endovascular treatments for lower limb PAD. Clinical data show improved clinical 
outcomes compared to bare metal stents (BMS). This budget impact analysis assessed 
the impact of introducing reimbursement for a paclitaxel DES in France. METHODS: 
An Excel-based model was developed to estimate the impact of a transition from BMS 
to DES over a 5-year horizon (15% in 2011 to 35% in 2015). Hospital episode sta-
tistics were used to estimate the 2011–2015 patient population. The analysis was 
conducted from the payer perspective and only direct costs of procedures were con-
sidered, based on GHM 2009 tariffs (stenting and revascularization) and LPPR tariffs 
(BMS and grafts). The main outcome was target lesion revascularization (TLR) in the 
superﬁ cial femoral artery (SFA) after primary stent placement: angioplasty, re-stenting, 
or bypass surgery. TLR rates were based on the paclitaxel drug-eluting SFA stent 
registry study and on BMS TLR rates reported in the literature (Years 1 and 2: 6% 
and 9% for the DES; 16% and 22% for average BMS) and extrapolated for years 3 
to 5. Net budget impact was expressed as the difference in cost between the scenario 
where the DES is progressively adopted versus the status quo (patients treated with 
BMS only). RESULTS: The base-case results show an incremental cost of c278,526 
in year 1, which is more than offset by increasing cost savings in all subsequent years 
(year 2: −c35,901; year 5: −c510,025), resulting in a cumulative 5-year net budget 
impact of −c727,649. One-way sensitivity analyses on key inputs continued to show 
cumulative 5-year cost savings. CONCLUSIONS: Reimbursement and consequent 
adoption of the paclitaxel DES would result in cost savings for the French health care 
payer, despite requiring an initial investment. This is due to savings associated with 
fewer SFA revascularization events after the primary intervention.
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OBJECTIVES: Aortic Stenosis (AS) is a severe cardiovascular condition and treatment 
often involves a major operation. For a subgroup of patients medical management 
(MM) is the only treatment option due to procedural risk. A transcatheter aortic valve 
implantation device “CoreValve,” is less invasive and allows for the implantation of 
a replacement valve in this patient group. However, CoreValve is more expensive than 
MM and introducing this technology into routine care would lead to an increase in 
National Health Service (NHS) spending. We estimated this budgetary impact using 
existing economic models. METHODS: In an Excel based Markov model CoreValve 
was compared to MM for inoperable patients. Parameters were derived from pub-
lished literature. Costs were taken from the most recent published sources. Decrements 
were applied to age-speciﬁ c EQ-5D population norms to generate QALYs. Incidence 
estimates were derived from information in a large national database. Projected ﬁ ve 
year uptake rates were provided by Medtronic. The outputs from the economic model 
were used for all relevant parameters. Case mix estimates were elicited from a clinical 
advisory board. RESULTS: Across all patients, the estimated incidence rate of AS was 
165 per million, 40% of these patients were assumed to be inoperable, 66 per million. 
The uptake rate of CoreValve in the inoperable group rose linearly from 0% to 50% 
over 5 years. When all inoperable patients were treated with MM the total budgetary 
cost was £13,454,000. When 50% of patients are treated with CoreValve and 50% 
with MM, the total budgetary cost increases to £49,706,000. Thus, the total burden 
to the NHS of 50% of inoperable patients receiving CoreValve would be £36,251,000. 
With a more optimistic ﬁ ve year uptake rate (75%) this increases to £54,852,000. 
CONCLUSIONS: Introducing CoreValve would result in an additional £36,251,000 
being spent by the UK NHS.
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OBJECTIVES: To calculate and compare costs of primary treatment of hypertension 
with candesartan/hydrochlorothiazide (HCT) or losartan/HCT in the Mexican Social 
Security Institute (IMSS). METHODS: An adaptation from Kjeldsen observational 
study of 14,100 patients diagnosed with hypertension and the costs’ sub analysis of 
Henriksson was made to have an approximation of incurred costs by IMSS when using 
candesartan/HCT or losartan/HCT in the primary hypertension treatment and its 
impact in reducing related cardiovascular events. First assumption for adaptation was 
to use only costs of combined therapies with HCT since monotherapies are not 
included in the IMSS formulary. Hospitalizations, laboratory tests and physician visits 
resource consumption reported by Kjeldsen were multiplied by IMSS 2010 unit costs. 
